HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE VP-16-213 FOR RECURRENT OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II STUDY

Pieter E. Postmus*, Nanno H MULDER, Hilly G De Vries- Hospers, Paula O.M Mulder, Annelies Maas, Aaf F. Meinesz, Dirk. Th Sleijfer, Elisabeth G.E. De Vries

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    6 Citaten (Scopus)

    Samenvatting

    n nine patients with recurrent or refractory small cell lung cancer a phase II study with high-dose cyclophosphamide and high-dose VP 16-213 with autologous bone marrow transplantation was performed. The regimen used was based on a previously reported phase I study. In eight of the nine evaluable patients a response was seen (six PR and two CR). One patient died of treatment related toxicity. Infection is the most important toxicity. The response duration was short. This combination is a suitable "late intensification' regimen for patients with minimal residual disease after standard dose induction chemotherapy.
    Originele taal-2English
    Pagina's (van-tot)1467-1470
    Aantal pagina's4
    TijdschriftEuropean journal of cancer & clinical oncology
    Volume21
    Nummer van het tijdschrift12
    DOI's
    StatusPublished - dec-1985

    Citeer dit